Last reviewed · How we verify
CD1579
CD1579 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.
CD1579 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | CD1579 |
|---|---|
| Also known as | Benzoyl Peroxide 2.5% Gel |
| Sponsor | Galderma R&D |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the production of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce skin inflammation and immune activation in inflammatory skin diseases. The selective PDE4 inhibition provides a targeted approach to modulating innate immune responses.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Nausea
- Diarrhea
- Headache
- Application site reactions
Key clinical trials
- Efficacy and Safety of CD5024 1% in Acne Vulgaris (PHASE2)
- A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients (PHASE1)
- Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris (PHASE3)
- Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. (PHASE3)
- Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |